RxDoctor Payments Data

Dean Taylor Reid

Psychiatric/Mental Health · Englewood, NJNPI 1295123248

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 342 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,865in general payments, 2019–2025

Across 342 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • Vanda Pharmaceuticals Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • AbbVie$1K
  • Neurocrine Biosciences, Inc.$1K
  • Alkermes, Inc.$656
  • plus $669 from 4 others

What the payments were for

  • Food & beverage$7,80199%
  • Education$641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,865 in reported general payments places this provider in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl33$46,765
RexultiBrexpiprazole18$26,634
Lurasidone Hcl19$5,381
Chlorpromazine Hcl20$4,843
Ramelteon35$3,097
Bupropion XlBupropion Hcl77$2,459
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine49$1,829
Atomoxetine Hcl25$1,774
Doxepin Hcl65$1,183
Naltrexone Hcl27$1,160
Clonazepam130$1,155
Disulfiram18$1,126
Gabapentin100$1,000
Quetiapine Fumarate115$984
Divalproex Sodium39$968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,250$46,76533 claims
Otsuka America Pharmaceutical, Inc.Rexulti$190$26,63418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Englewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →